Alpha-glucosidase is responsible for the hydrolysis of terminal, non-reducing 1,4-linked alpha-D-glucose residues, which releases alpha-D-glucose. It is a lysosomal hydrolase that is required for the degradation of a small percentage (1-3%) of cellular glycogen in humans. Deficiency of this enzyme results in glycogen-storage disease type II (GSDII), also referred to as Pompe disease, an autosomal recessive disorder. Structurally normal glycogen is accumulated in the lysosomes and cytoplasm in affected patients, primarily in muscle tissues. Excessive glycogen storage within lysosomes may interrupt normal functioning of other organelles and leads to cellular injury. In turn, this leads to enlargement and dysfunction of the entire organ involved (eg: cardiomyopathy and muscle weakness). It has been reported that the improper folding and trafficking of alpha-glucosidase resulting from genetic mutations may account for a significant number of Pompe patients. 1-deoxynojirimycin, an inhibitor of alpha-glucosidase, was reported to exhibit pharmacological chaperone activity, which significantly increases the mutant enzyme activity in cells. We optimized this alpha-glucosidase assay in 1536-well plate format for identification of novel small molecule inhibitors or activators with structures other than the sugar analogs in order to develop new pharmacological chaperones. Previous assays of alpha-Glucosidase have utilized a non-natural fluorescent substrate to probe enzyme activity. The present assay measures enzyme activity on glycogen using a coupled-assay system to glucose oxidase. This is an enzyme assay using glycogen from bovine liver (Sigma catalog #: G0885) as the substrate and recombinant human alpha-glucosidase as the enzyme preparation. Upon hydrolysis of the substrate, the glucose product can be detected using the Amplex Red Glucose Oxidase Assay Kit (Invitrogen catalog #: A22189). The product of this reaction can be read with a fluorescence plate reader with an excitation at 573 nm and an emission at 610 nm. Data were normalized to the controls for basal activity (without enzyme) and 100% activity (with enzyme). The AC50 values were determined from concentration-response data modeled with the standard Hill equation. Assay buffer for enzyme reaction: 50 mM citric acid (titrated with potassium phosphate to pH 5.0), 0.01% Tween-20 (pH 5.0 is an optimal condition for this enzyme assay) Assay buffer for Amplex Red reaction: Tris-HCl, pH 7.5 1536-well assay protocol for the alpha-glucosidase assay: (1) Add 2 ul/well alpha-glucosidase enzyme solution (4 nM final) (2) Add 23 nL compounds in DMSO solution. The final titration was 0.7 nM to 77 uM. (3) Add 1 ul of glycogen substrate solution (30 ug) (4) Incubate at 37 C for 40 min (5) Add 2 ul tris-HCl buffer with Amplex Red reagents (6) Incubate 45 min at room temperature. (7) Detect the assay plate in a ViewLux plate reader (PerkinElmer) with Ex=573 nm and Em=610nm.
bao:BAO_0001077 "1466" ; # "is alternate confirmatory assay of" -> "1466"
bao:BAO_0001077 "2242" ; # "is alternate confirmatory assay of" -> "2242"
bao:BAO_0000812 "1473" ; # "has summary assay" -> "1473"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0001082 bao:BAO_0001098 ; # "has alternate assay conditions" -> "alternate assay conditions"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000222 ; # "has participant" -> "generic hydrolase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 "hydrolase activity assay" ; # "is bioassay type of" -> "hydrolase activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0000139 ; # "has assay method" -> "direct enzyme activity measurement method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> bao:BAO_0000484 ; # "has assay design method" -> "enzyme inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> bao:BAO_0000493 ; # "has assay design method" -> "enzyme activation"
bao:BAO_0000207 bao:BAO_0000363 ; # "has detection method" -> "fluorescence intensity"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "To screen for inhibitors and activators of human alpha-Glucosidase as a potential chaperone treatment of pompe disease" ; # "screening campaign name" -> "To screen for inhibitors and activators of human alpha-Glucosidase as a potential chaperone treatment of pompe disease"
bao:BAO_0002853 "qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen" ; # "has assay title" -> "qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "37 degree celsius" ; # "substrate incubation temperature" -> "37 degree celsius"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "40 minute" ; # "substrate incubation time" -> "40 minute"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
bao:BAO_0000740 "no enzyme" ; # "has assay control" -> "no enzyme"
bao:BAO_0000740 bao:BAO_0000334 ; # "has assay control" -> "background control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Wei Zheng" ; # "material entity assay provider" -> "Wei Zheng" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0001038 ; # "has participant" -> "Tween 20" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_27780> ; # "has role" -> "detergent"
bao:BA0_0090012 bao:BAO_0000927 ; # "has participant" -> "Glycogen" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "Lysosomal alpha-glucosidase" ; # "has participant" -> "Lysosomal alpha-glucosidase"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P10253" ; # "uniprot ID" -> "P10253"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0001006 ; # "has participant" -> "Resorufin"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BAO_0002857 bao:BAO_0002153 ; # "has signal direction" -> "signal increase corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000816 ; # "has assay kit" -> "Amplex Red Glucose/Glucose Oxidase Assay Kit"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000677 ; # "has manufacturer" -> "Invitrogen" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000691 ; # "uses detection instrument" -> "ViewLux ultraHTS Microplate Imager"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "573 nanometer" ; # "has excitation wavelength value" -> "573 nanometer"
bao:BAO_0002918 "610 nanometer" ; # "has emission wavelength value" -> "610 nanometer"
bao:BAO_0000208 bao:BAO_0000186 ; # "has endpoint" -> "AC50"
bao:BAO_0000337 bao:BAO_0000656 ; # "has percent response" -> "efficacy"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002787 "6" ; # "has concentration-point number" -> "6"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0000196 bao:BAO_0000087 ; # "has mode of action" -> "activation"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie" ; # "Annotated by" -> "kunie"
